A blue and black background

Description automatically generated

**Target audience:** Pediatric Hematology/Oncology Providers and Nurses

**Learning objectives:**

* Blinatumumab improved outcomes in all pediatric SR ALL patients
* BKT inhibitor Rilzabrutinib improved platelet count in adult chronic ITP patients
* Emerging therapies for RBC membrane disorders include Mitapivat (PK activator), gene therapy combining 2 half c-DNAs and trans-ligating 2 mRNAs for large RBC membrane genes.

**Speaker Elizabeth Yang, MD**

ASH 2024 Annual Meeting Review

**PSV Hemonc Wednesday Educational Conference**

**Accreditation:** The Inova Office of Continuing Medical Education is accredited by the Medical Society of Virginia to provide continuing medical education for physicians.

**Credit designation:** The Inova Office of Continuing Medical Education designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians may claim up to 1.0 credit in Type 1 CME on the Virginia Board of Medicine Continued Competency and Assessment Form required for renewal of an active medical license in Virginia.

**Location: Zoom**

**January 15, 2025**

**3:30p.m. – 4:30 p.m.**

**To claim credit,   
text COWFOZ   
to 703.260.9391**

**Inova.org**

**PSV Hematology/Oncology**